Recently, following the granting of Pediatric Rare Disease Designation (RPDD) by the U.S. Food and Drug Administration (FDA), Innovecbio's IVB105 injection has received Orphan Drug Designation (ODD).
IVB105 is an optogenetic gene therapy drug developed based on Innovecbio's self-developed novel AAV vector.IVB105, through effective delivery by a novel AAV vector, can achieve specific expression in target cells and generate robust visual evoked potentials under white, green, and blue light conditions, restoring light perception in blind animals.
InnoVec Biotherapeutics Inc. (Innovecbio) is a clinical-stage gene therapy company driven by vector innovation. The company is committed to developing gene therapy delivery tools suitable for human use, addressing the challenges of translating delivery tools from animals to humans. Its goal is to discover gene delivery tools for all tissues and organs, enabling gene therapy to be widely applied to both rare and common diseases. InnoVec Biotherapeutics boasts efficient teams in technology development, pipeline research, process optimization, and clinical operations, establishing a leading technology development platform that covers multiple disease areas, including ophthalmology, neurology, and muscular diseases. Several innovative products have already entered the IIT and IND stages.In order to allow everyone to learn and communicate with each other better,"WeChat Official Account 'Cell Gene Therapy' Team"A WeChat group for cell therapy and gene therapy discussions has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。
Article Recommendation(Click the article title below to open the original text)：
WuXi AppTec Responds to Rumors of Selling Cell and Gene Therapy Business, Citing Uncertainty
Guangdong Issues New Policy to Support the R&D of Innovative Biologics such as Gene Therapy and Cell Therapy, Focusing on Developing New Fields and Tracks like Gene Technology, Cell Therapy, and Synthetic Biology
2024 Nobel Prize in Physics Announced
New Drug for ALS Approved! Biogen's "Tofersen Injection" Launched in China
Nature Website Headline! Chinese Scholars Publish the World's First Universal CAR-T Treatment Achievement
2024 Nobel Prize in Physiology or Medicine Announced!
$4.5 Billion: Lilly Invests in New Drug Development and Manufacturing Center
InnoVec Biotherapeutics' iPS Cell-Derived Cell Therapy IND Accepted for Review
WuXi AppTec, WuXi Biologics Respond to Rumors of Selling Business
Multiple Patients Have Stopped Standard Treatment! Positive Early Clinical Results for Gene Therapy
World's First Approved Universal Cell Therapy for Eye Diseases Officially Launched
Seven Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields
Fosun Pharma to Build China's Largest and Most Comprehensive Cell Therapy Pipeline in Shanghai, Strengthening R&D of Innovative Oncology Drugs
Major Policy Breakthrough in Clinical Application and Charging of Stem Cell Technology May Be Coming! Hainan Releases "Regulations on the Promotion of Biomedical New Technologies in Boao Lecheng International Medical Tourism Pilot Zone of Hainan Free Trade Port (Draft)"
Multinational pharmaceutical companies accelerate layout in China market, cell and gene therapy become new growth points
NHFPC: Measures for the Administration of IIT Research Conducted by Medical and Health Institutions to Take Effect on October 1 (with Interpretation)
Innovecbio's CAR-T Cell Therapy "Najiolun Sai" New Indication Submitted for Marketing Approval
Significantly Improve the Translation Efficiency of RNA Drugs: Wang Xiao's Team Achieves Latest Results in mRNA Design and Optimization Technology
RiboBio Partners with PHEIRON for AI-Assisted RNA Drug Development
Competitive Landscape of Gene Editing Therapy in China
Statement:Content sourced fromOfficial Company, This article aims at knowledge sharing. All content is for reference only and does not constitute any advice.
